Semaglutide Hair Loss: What the Label Reports and Why It Happens
The short answer
Hair loss is a labelled Wegovy (semaglutide) side effect: 3.3% of people on 2.4 mg reported it in the pooled obesity trials against 1% on placebo, and 5.8% on 7.2 mg. The label says the hair loss was associated with weight reduction, which fits temporary shedding after rapid weight loss (telogen effluvium).
Hair loss is on the semaglutide labels, and the Wegovy label says plainly that the hair loss reactions were associated with weight reduction. That points to the usual explanation, a temporary shedding phase called telogen effluvium, rather than the drug acting on hair follicles. This page gives the label numbers, the explanation, and what is and is not known. It is a research reference, not medical advice.
What the labels report
| Label | Hair loss on drug | Placebo | Notes |
|---|---|---|---|
| Wegovy 2.4 mg, pooled obesity trials (Studies 2, 3, 4) | 3.3% | 1% | 4% in women and 0.9% in men on drug; 2% and 0% on placebo |
| Wegovy 7.2 mg, 72-week trials | 5.8% (8.4% in women, 0.2% in men) | 1.0% | The 2.4 mg arm in the same trials: 3.3% (5.4% in women, 0 in men) |
| Wegovy 2.4 mg, adolescent trial | 4% | None | Pediatric trial |
| Ozempic | Alopecia is listed among postmarketing reports | Not applicable | Ozempic is labelled for type 2 diabetes, not weight reduction |
| Zepbound 5, 10, 15 mg (tirzepatide, for comparison) | 5%, 4%, 5% | 1% | Pooled SURMOUNT-1 and SURMOUNT-2 |
Sources: the Wegovy label (revised June 2026), the Ozempic label (revised May 2026) and the Zepbound label (revised August 2026). The Wegovy label states that hair loss in injection-treated patients was associated with weight reduction.
Why hair sheds during weight loss
Telogen effluvium is a common cause of diffuse, non-scarring hair loss, usually precipitated by physiological stress such as childbirth or sudden weight loss, and it has a high rate of remission (J Dermatol Sci 2021). It is not a direct effect of a drug on follicles. A second review describes excessive shedding as a common complaint, mostly in women, and cautions clinicians against dismissing it (Clin Cosmet Investig Dermatol 2019). The pattern in the label fits: the rates are higher in women than in men, and higher at the 7.2 mg dose, where weight loss is greater.
What is not established
- The labels do not say how long shedding lasts on semaglutide or whether it fully resolves. The telogen effluvium reviews report a high rate of remission in general, not in GLP-1 users specifically.
- Observational cohort studies of hair loss with semaglutide and tirzepatide have been published in dermatology journals (J Am Acad Dermatol 2025, J Am Acad Dermatol 2026). We could not read their results in full, so we do not quote them, and the label trial rates above are the figures we can stand behind.
- No label names a treatment. The telogen effluvium review states there are no targeted treatments for managing it (J Dermatol Sci 2021).
- Thinning that continues at the temples or crown, or that does not settle, is a different question from shedding that follows weight loss and belongs with a dermatologist.
Related reading
The same mechanism is discussed for newer drugs in retatrutide and hair loss. For options on the hair side, see peptides for hair loss and copper peptides for hair, and for the wider side effect profile semaglutide side effects. Eating on a GLP-1 is covered in what to eat on semaglutide. If you are comparing the brands, see Ozempic vs Wegovy.
Calculate your draw for semaglutide
Working from a semaglutide vial? Enter the vial strength, the bacteriostatic water you added and your dose, and get the exact mark on the syringe. Free, no signup.
Open the semaglutide calculator peptulator.com, the Bureau's independent toolNot sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the six vendors we score.
Build your stack, 2 minutesFrequently asked questions
Does semaglutide cause hair loss?
It is a labelled side effect of Wegovy: 3.3% on 2.4 mg and 5.8% on 7.2 mg, against 1% on placebo. The label says the hair loss reactions were associated with weight reduction, and shedding after rapid weight loss is a recognised cause of hair loss on its own.
Is hair loss from Ozempic permanent?
The Ozempic and Wegovy labels do not say. Telogen effluvium, the usual explanation for hair shedding after sudden weight loss, has a high rate of remission, but no study we could read reports how long it lasts in semaglutide users.
Who gets hair loss on semaglutide?
In the Wegovy label it is reported more in women than in men: 4% against 0.9% in the 2.4 mg pool, and 8.4% against 0.2% on 7.2 mg.
Do tirzepatide users lose hair too?
Yes. The Zepbound label lists hair loss at 4% to 5% on 5 to 15 mg against 1% on placebo.
Sources (checked 6 November 2026)
- Wegovy prescribing information, Novo Nordisk, revised 6/2026. Checked 6 November 2026.
- Ozempic prescribing information, Novo Nordisk, revised 5/2026. Checked 6 November 2026.
- Zepbound prescribing information, Eli Lilly, revised 8/2026, DailyMed. Checked 6 November 2026.
- Go et al, Telogen effluvium: a review of the science and current obstacles, Journal of Dermatological Science, 2021. Checked 6 November 2026.
- Rebora, Telogen effluvium: a comprehensive review, Clinical, Cosmetic and Investigational Dermatology, 2019. Checked 6 November 2026.
- Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study, Journal of the American Academy of Dermatology, 2025. Checked 6 November 2026.
- Risk of new-onset hair loss with semaglutide and tirzepatide: a TriNetX cohort study, Journal of the American Academy of Dermatology, 2026. Checked 6 November 2026.
Label figures are from the Wegovy label revised June 2026. Labels and trial records change; the leaflet in your box and your prescriber come first. Educational content, not medical advice.